Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

New York State Grants Final Approval for miRview® lung; Expands Access for Rosetta Genomics' microRNA Diagnostic for



  New York State Grants Final Approval for miRview® lung; Expands Access for
    Rosetta Genomics' microRNA Diagnostic for Identification of Four Major
                           Subtypes of Lung Cancer

New, Targeted Therapies Make Accurate Classification of Lung Cancer
Increasingly Important

PR Newswire

PHILADELPHIA and REHOVOT, Israel, Nov. 6, 2012

PHILADELPHIA and REHOVOT, Israel, Nov. 6, 2012 /PRNewswire/ -- Rosetta
Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based
molecular diagnostic assays, announces that the New York State Department of
Health has given the Company final approval for its miRview^® lung assay
following conditional approval issued in June 2012.  With this final approval,
Rosetta Genomics can continue to offer the miRview^® lung assay in all 50 U.S.
states. New York is the only U.S. state that requires an independent
regulatory review process for laboratory-developed tests.

miRview^® lung is the Company's proprietary microRNA-based assay that can
accurately differentiate between the four main subtypes of lung cancer using
small amounts of tumor cells. 

"We are pleased to have final New York State approval for our micro-RNA-based
miRview lung assay.  This represents an important validation of our technology
as many jurisdictions around the world recognize the rigor of review in the
state of New York.  With the introduction of targeted lung cancer therapies,
along with new targeted drugs entering the clinical arena, accurate
classification of lung cancer is becoming increasingly important to better
assess efficacy profiles and to enhance treatment strategies," noted Kenneth
A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "We look
forward to continuing to offer this important assay to the benefit of patients
and physicians throughout the U.S. where, according to the National Cancer
Institute, there are an estimated 226,000 new cases of lung cancer and an
estimated 160,000 lung cancer related deaths expected in 2012."

About miRview^® lung
miRview lung accurately identifies the four main subtypes of lung cancer with
a sensitivity of 95%, using very small pre-operative biopsies such as fine
needle aspirate and cytological samples.  The assay differentiates
neuroendocrine tumors from non-small cell lung tumors (NSCLC), and then
further subtypes neuroendocrine tumors into small cell lung cancer and
carcinoid; and subtypes NSCLC tumors into squamous and non-squamous.   

About miRview^® Products
miRview^® products are a series of microRNA-based molecular diagnostic
products offered by Rosetta Genomics. The miRview^® mets² assay accurately
identifies the primary tumor type in patients with primary or metastatic
Cancer of Unknown or Uncertain primary (CUP). miRview^® meso diagnoses
mesothelioma, a cancer connected to asbestos exposure.  miRview^® lung
accurately identifies the four main subtypes of lung cancer. miRview^® kidney
accurately classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. 
miRview^® assays are designed to provide objective diagnostic data; it is the
treating physician's responsibility to diagnose and administer the appropriate
treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000
patients a year may benefit from the miRview^® mets² test, 60,000 from
miRview^® meso, 54,000 from miRview^® kidney and 226,000 patients from
miRview^® lung. The Company's assays are offered directly by Rosetta Genomics
in the U.S., and through distributors around the world. For more information,
please visit www.mirviewdx.com. Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics.  Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating to  the
market acceptance of Rosetta's miRview^® assays, particularly miRview^® lung,
as well as the increasing importance of accurate classification and subtyping
of lung cancer and Rosetta's capitalization of its microRNA platform
constitute forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995.  Actual
results may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including those risks
more fully discussed in the "Risk Factors" section of Rosetta's Annual Report
on Form 20-F for the year ended December 31, 2011 as filed with the SEC.  In
addition, any forward-looking statements represent Rosetta's views only as of
the date of this release and should not be relied upon as representing its
views as of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.

Company Contact:              Investor Contacts:
Rosetta Genomics              LHA
Ken Berlin, President & CEO   Anne Marie Fields
(215) 382-9000, ext. 326      (212) 838-3777
investors@rosettagenomics.com afields@lhai.com
                              or
                              Bruce Voss
                              (310) 691-7100
                              bvoss@lhai.com

SOURCE Rosetta Genomics
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement